NASDAQ:OPT Opthea (OPT) Stock Price, News & Analysis $3.41 +0.23 (+7.23%) As of 03/28/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Opthea Stock (NASDAQ:OPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Opthea alerts:Sign Up Key Stats Today's Range$3.25▼$3.4850-Day Range$3.07▼$5.9252-Week Range$1.79▼$6.30Volume3,000 shsAverage Volume26,061 shsMarket Capitalization$524.84 millionP/E RatioN/ADividend YieldN/APrice Target$1.33Consensus RatingHold Company OverviewOpthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Read More… Remove Ads Opthea Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreOPT MarketRank™: Opthea scored higher than 14% of companies evaluated by MarketBeat, and ranked 899th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingOpthea has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageOpthea has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Opthea's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Opthea are expected to grow in the coming year, from ($1.39) to ($0.67) per share. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.35% of the float of Opthea has been sold short.Short Interest Ratio / Days to CoverOpthea has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Opthea has recently increased by 20.66%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpthea does not currently pay a dividend.Dividend GrowthOpthea does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.35% of the float of Opthea has been sold short.Short Interest Ratio / Days to CoverOpthea has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Opthea has recently increased by 20.66%, indicating that investor sentiment is decreasing significantly. News and Social Media1.4 / 5News Sentiment-0.42 News SentimentOpthea has a news sentiment score of -0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 41 news articles for Opthea this week, compared to 3 articles on an average week.MarketBeat Follows5 people have added Opthea to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Opthea insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Opthea is held by insiders.Percentage Held by Institutions55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Opthea's insider trading history. Receive OPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter. Email Address OPT Stock News HeadlinesOpthea Ends Development of Sozinibercept in Wet AMDMarch 31 at 7:09 PM | marketwatch.comOpthea terminates COAST trial, announces ShORe trial misses endpointMarch 31 at 7:09 PM | markets.businessinsider.comElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.April 1, 2025 | Brownstone Research (Ad)Opthea Announces Decision to Discontinue Wet AMD TrialsMarch 31 at 12:01 AM | globenewswire.comOpthea Limited’s Securities Suspended Due to Financial ConcernsMarch 30 at 11:45 PM | tipranks.comJPMorgan Chase Acquires Substantial Stake in Opthea LimitedMarch 30 at 5:53 PM | tipranks.comFY2025 EPS Estimates for Opthea Reduced by Leerink PartnrsMarch 29 at 2:05 AM | americanbankingnews.comOpthea Limited (NASDAQ:OPT) Receives $1.33 Average Target Price from BrokeragesMarch 29 at 1:05 AM | americanbankingnews.comSee More Headlines OPT Stock Analysis - Frequently Asked Questions How have OPT shares performed this year? Opthea's stock was trading at $3.93 on January 1st, 2025. Since then, OPT stock has decreased by 13.2% and is now trading at $3.41. View the best growth stocks for 2025 here. When did Opthea IPO? Opthea (OPT) raised $161 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 9,300,000 shares at a price of $17.26 per share. Citigroup and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers. How do I buy shares of Opthea? Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Opthea own? Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include PayPal (PYPL), Sunrun (RUN), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), QUALCOMM (QCOM), Ross Stores (ROST) and Zendesk (ZEN). Company Calendar Today3/31/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OPT CIK1815620 Webwww.opthea.com Phone61-3-9826-0399FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$1.33 High Stock Price Target$2.00 Low Stock Price Target$1.00 Potential Upside/Downside-60.9%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.94 Quick Ratio2.94 Sales & Book Value Annual Sales$87,666.00 Price / Sales5,986.77 Cash FlowN/A Price / Cash FlowN/A Book Value($0.56) per share Price / Book-6.09Miscellaneous Outstanding Shares153,911,000Free Float148,981,000Market Cap$524.84 million OptionableNot Optionable Beta1.12 7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:OPT) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.